Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2015
- Source ID
- 10.1016/j.bbmt.2015.07.028
Entities
People
- Alan M. Miller
- Alberto Mussetti
- Andreas Klein
- Anita D'Souza
- Anna M. Sureda
- Asad Bashey
- César O. Freytes
- David G. Maloney
- Evgeny Klyuchnikov
- Ginna G. Laport
- Grace H. Ku
- Hillard M Lazarus
- Jeanette Carreras
- Jonathon B. Cohen
- Kwang Woo Ahn
- Leona A. Holmberg
- Mark S. Hertzberg
- Mehdi Hamadani
- Mohamed A Kharfan-Dabaja
- Nicolaus M. Kröger
- Parameswaran N. Hari
- Ravi Vij
- Richard F. Olsson
- Robert Peter Gale
- Saad Z. Usmani
- Shimon Slavin
- Siddhartha Ganguly
- Sonali M Smith
- Ulrike Bacher
- Veronika Bachanova
- William A. Wood
Organizations
- ARIAD Pharmaceuticals
- Actinium Pharmaceuticals (United States)
- Amgen
- Blue Cross Blue Shield Association
- Celgene
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- GSK
- Genzyme
- Health Resources and Services Administration
- HistoGenetics (United States)
- Incyte
- Kiadis Pharma (Netherlands)
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co.
- Milliman
- Miltenyi Biotec
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Osiris Therapeutics
- Otsuka (United States)
- Roche (United States)
- Roswell Park Comprehensive Cancer Center
- Sanofi-Aventis
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- St. Baldrick's Foundation
- StemCyte
- Swedish Orphan Biovitrum
- Tarix Orphan (United States)
- United States Public Health Service
- University of Minnesota
- University of Utah